StocksTelegraph
S&P 500—NASDAQ—DOW—RUSSELL—
NASDAQ · CRBU·Healthcare

Caribou Biosciences, Inc. Stock Analysis & AI Score

Caribou Biosciences, Inc. (CRBU) has an ST Score of 34.7 (C-), driven by its Forecast (A) and held back by its Momentum (F). Analysts rate it Buy with a $5.00 price target (+300.0% upside).

Market Closed
$1.25
Prev Close
—
Market Cap
—
Day Range
—
52W Range
—
P/E
—
EPS (TTM)
—
Volume
—
Avg —
Beta
—
35
ST Score
34.7/100C-

Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.

As of
AI Daily Briefing
Analysis by AI
Price History
—
Technical Indicators
FMP
Earnings Surprises
Analyst Forecast
Revenue Mix

Company Information

Employees—
CEO—
SectorHealthcare
IndustryBiotechnology
IPO Date—
Website—
Country—
ExchangeNASDAQ

SEC Filings

Annual Report (10-K)

Filing DateAcceptedLink
Loading…

Quarterly Report (10-Q)

Filing DateAcceptedLink
Loading…
Analyst Price Target
ESG Score
Latest News

ST Score

CRBU
34.7out of 100
Grade C-

Caribou Biosciences, Inc. (CRBU) has an ST Score of 34.7 (C-), driven by its Forecast (A) and held back by its Momentum (F). Analysts rate it Buy with a $5.00 price target (+300.0% upside).

Strongest
ForecastA
Weakest
MomentumF
All factor grades
  • ForecastA
  • ValuationC
  • Financial StrengthC
  • GrowthC-
  • ProfitabilityD
  • MomentumF
  • Piotroski3/9
Score methodology
Press Releases

Contact

CRBU stock: frequently asked questions

What is CRBU's ST Score?

Caribou Biosciences, Inc. (CRBU) has an ST Score of 34.7 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Is CRBU a buy, hold, or sell?

Analysts rate CRBU a Buy, with a price target of $5.00 (+300.0% vs the current price). Our ST Score grades it C- (34.7/100). The ST Score is a data-driven signal, not a recommendation.

What are CRBU's factor grades?

Valuation C, Profitability D, Financial Strength C, Momentum F, Growth C-, Forecast A.

What is CRBU's valuation grade?

Caribou Biosciences, Inc. (CRBU) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

What is CRBU's growth grade?

Caribou Biosciences, Inc. (CRBU) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

What is CRBU's profitability grade?

Caribou Biosciences, Inc. (CRBU) earns a profitability grade of D, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

What is CRBU's financial strength grade?

Caribou Biosciences, Inc. (CRBU) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

What is the analyst price target for CRBU?

The average analyst price target for Caribou Biosciences, Inc. (CRBU) is $5.00 from 9 analysts, which is +300.0% versus the recent price of $1.25.

What is CRBU's Piotroski score?

Caribou Biosciences, Inc. (CRBU) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.